UK-based biotech Roquefort Therapeutics (LSE: ROQ) has announced that its mesodermal killer (MK) cell program has reached a significant milestone.
The company’s MK cells are a proprietary and novel class of cellular medicine. While MK cells kill cancer cells directly, their more profound effect is the activation of natural killer (NK) cells.
This direct killing of cancer cells and activation of NK cells to increase cytotoxicity have each been demonstrated in validated in vivo models of lymphoma and myeloma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze